Patient-reported outcomes in patients with rheumatoid arthritis treated with baricitinib: A prospective observational study in Japan
Modern Rheumatology · 2026
DOI: 10.1093/mr/roag032 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Modern Rheumatology, 2026. Verfasst von Yuko Kaneko und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Sulfonamides, Arthritis, Rheumatoid, Azetidines, Patient Reported Outcome Measures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Drug Development & Medical Affairs.
Abstract (Originalsprache)
Objectives
This real-world study evaluated the effectiveness of baricitinib on the activities of daily living and health-related quality of life in patients with rheumatoid arthritis in Japan, and it explored the association between early pain and fatigue improvements and 12-month remission.
Methods
The study involved patients with rheumatoid arthritis aged ≥20 who initiated baricitinib and were followed for 12 months. Patient-reported outcomes were assessed using a visual analogue scale, the Locomo 5, the EQ-5D-5L, and the SF-36 subscales.
Results
The study included 353 patients (mean age of 63.4 years). Baricitinib substantially reduced pain levels from a mean (SD) of 48.4 (26.5) mm, fatigue levels from 42.3 (28.3) mm, and morning stiffness from 51.8 (126.9) min at baseline, to 25.2 (21.4) mm, 24.3 (22.7) mm, and 15.8 (38.7) min, respectively, at 12 months. Clinically meaningful improvements were observed in activities of daily living [Locomo 5 scores: 6.9 (5.7) to 4.7 (5.3)] and health-related quality of life [EQ-5D-5L index scores: 0.700 (0.217) to 0.829 (0.166)] over 12 months. Logistic regression analysis revealed that early improvements in pain and fatigue were predictive of disease remission at 12 months.
Conclusions
Baricitinib improved patient-reported outcomes in patients with rheumatoid arthritis in Japan, with early symptom relief predicting mid-term disease remission. To complement this abstract, a video abstract is available online.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan.
- Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan.
- Department of Rheumatology/Rheumatic Disease Center, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsugagun, Tochigi, Japan.
Förderung
- Japan Drug Development & Medical Affairs
Zitieren
APA
Kaneko, Y., Tsujimoto, N., Sato, I., Kojima, T., & Ikeda, K. (2026). Patient-reported outcomes in patients with rheumatoid arthritis treated with baricitinib: A prospective observational study in Japan. Modern Rheumatology. https://doi.org/10.1093/mr/roag032
Vancouver
Kaneko Y, Tsujimoto N, Sato I, Kojima T, Ikeda K. Patient-reported outcomes in patients with rheumatoid arthritis treated with baricitinib: A prospective observational study in Japan. Modern Rheumatology. 2026. doi:10.1093/mr/roag032
BibTeX
@article{Kaneko2026,
author = {Kaneko, Yuko and Tsujimoto, Naoto and Sato, Izumi and Kojima, Taisuke and Ikeda, Kei},
title = {Patient-reported outcomes in patients with rheumatoid arthritis treated with baricitinib: A prospective observational study in Japan},
journal = {Modern Rheumatology},
year = {2026},
doi = {10.1093/mr/roag032}
}
EUVIMED